Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMoDL-B: Bortezomib in DLBCL
NCT01324596Phase 3Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2011
- Primary completion
- Apr 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by University Hospital Southampton NHS Foundation Trust. Started Apr 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01324596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324596.